HCC patients who respond to immunotherapy with PD-(L)1 undergo a single FMT, while HCC patients who fail to achieve complete or partial response to atezolizumab/bevacizumab continue to receive atezolizumab/bevacizumab every 21 days according to the protocol after the single FMT. Here, CD274 is linked to hepatocellular carcinoma.